PHAP I Antibody
Code | Size | Price |
---|
PSI-3151-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-3151-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
PHAP I Antibody: LANP, MAPM, PP32, HPPCn, PHAP1, PHAPI, I1PP2A, C15orf1, LANP, Acidic leucine-rich nuclear phosphoprotein 32 family member A, Acidic nuclear phosphoprotein pp32
Application Note:
WB: 1 μg/mL; IHC: 2 μg/mL; IF: 20 μg/mL.
Antibody validated: Western Blot in human, mouse and rat samples; Immunohistochemistry in mouse samples; Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human, mouse and rat samples; Immunohistochemistry in mouse samples; Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
PHAP I Antibody: Apoptosis is related to many diseases and development. Caspase-9 plays a central role in cell death induced by a variety of apoptosis activators. Cytochrome c, after released from mitochondria, binds to Apaf-1, which forms an apoptosome that in turn binds to and activate procaspase-9. Activated caspase-9 cleaves and activates the effector caspases (caspase-3, -6 and -7), which are responsible for the proteolytic cleavage of many key proteins in apoptosis. The tumor suppressor putative HLA-DR-associated proteins (PHAPs) were recently identified as important regulators of mitochondrion apoptosis. PHAP appears to facilitate apoptosome-medicated caspase-9 activation and to stimulate the mitochondrial apoptotic pathway. PHAP was also shown to oppose both Ras- and Myc-medicated cell transformation.
Background References:
- Jiang et al. Science. 2003;299(5604):223-6.
- Nicholson and Thornberry. Science. 2003 10;299(5604):214-5.
Buffer:
PHAP I Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (85%)
Immunogen:
Anti-PHAP I antibody (3151) was raised against a peptide corresponding to 14 amino acids near the carboxy terminus of human PHAP I .
The immunogen is located within the last 50 amino acids of PHAP I.
The immunogen is located within the last 50 amino acids of PHAP I.
NCBI Gene ID #:
8125
NCBI Official Name:
acidic (leucine-rich) nuclear phosphoprotein 32 family, member A
NCBI Official Symbol:
ANP32A
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 29kD
Observed: 29 kD
Observed: 29 kD
Protein Accession #:
P39687
Protein GI Number:
730318
Purification:
PHAP I Antibody is DEAE purified.
Research Area:
Apoptosis
SPECIFICITY:
This polyclonal antibody has no cross-reaction to PHAP I2a and PHAP III.
Swissprot #:
P39687
User NOte:
Optimal dilutions for each application to be determined by the researcher.
References
- Schafer et al. Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells. Cancer Res. 2006;66(4):2210-8. PMID: 16489023
- Kurokawa et al. A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. Sci Signal. 2013;6(274):ra32. PMID: 23652204
- Parrish. Regulation of Apoptosis Following Mitochondrial Cytochrome c Release. Department of Pharmacology and Molecular Cancer Biology, Duke University. PhD Thesis, 2010.
Related Products
Product Name | Product Code | Supplier | PHAP I Peptide | PSI-3151P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|